☆ 4.7 Meeting Abstract

A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 23, Issue 16, Pages 200S-200S

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/jco.2005.23.16_suppl.3036

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.